help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iwasaki, Y.
Right arrow Articles by Tomita, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iwasaki, Y.
Right arrow Articles by Tomita, A.

Journal of Clinical Endocrinology & Metabolism, Vol 70, 534-539, Copyright © 1990 by Endocrine Society

ARTICLES

Osmoregulation of plasma vasopressin in myxedema

Y Iwasaki, Y Oiso, K Yamauchi, K Takatsuki, K Kondo, H Hasegawa and A Tomita
Department of Internal Medicine, Nagoya University School of Medicine, Japan.

We studied osmoregulation of plasma vasopressin (AVP) in eight patients with untreated myxedema due to primary hypothyroidism. All patients had severe thyroid hormone deficiency due to chronic thyroiditis and had been receiving no medication at the time of this study. AVP release was defined by 5% hypertonic saline infusion test in all patients, and urinary diluting capacity was estimated by the iv water-loading tests in five patients. Plasma AVP was measured by sensitive and specific RIA. The mean basal plasma AVP level in the patients (0.5 +/- 0.1 pmol/L) was significantly lower (P less than 0.01) than that in normal adults (2.5 +/- 0.5 pmol/L). During hypertonic saline infusion, the rise in plasma AVP was normal or subnormal in all patients. In two patients who showed mild to moderate hyponatremia in the basal state and mild urinary diluting defect during water loading, plasma AVP was appropriately suppressed in each case. These results indicate that inappropriate elevation of plasma AVP is not common in myxedema, and that impaired water excretion is due mainly to AVP-independent mechanisms.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Schmitt, E. Klussmann, T. Kahl, D. H. Ellison, and S. Bachmann
Renal expression of sodium transporters and aquaporin-2 in hypothyroid rats
Am J Physiol Renal Physiol, May 1, 2003; 284(5): F1097 - F1104.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
T. J. Vachharajani, F. Zaman, and K. D. Abreo
Hyponatremia in Critically Ill Patients
J Intensive Care Med, January 1, 2003; 18(1): 3 - 8.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. W. Park, Y. S. Shin, S. J. Ahn, S. Y. Kim, E. J. Choi, Y. S. Chang, and B. K. Bang
Thyroxine treatment induces upregulation of renin-angiotensin-aldosterone system due to decreasing effective plasma volume in patients with primary myxoedema
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1799 - 1806.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society